

Blepharitis Treatment Pipeline Review H2 2016

Global Blepharitis Drugs and Companies Pipeline Review H2 2016

PUNE, INDIA, September 19, 2016

/EINPresswire.com/ -- Summary

The report provides comprehensive information on the therapeutics under development for [Blepharitis](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects.

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.



Complete Report @ <https://www.wiseguyreports.com/reports/643474-blepharitis-pipeline-review-h2-2016>

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Blepharitis
- The report reviews pipeline therapeutics for Blepharitis by companies and universities/research

institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Blepharitis therapeutics and enlists all their major and minor projects
- The report assesses Blepharitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Blepharitis

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/643474-blepharitis-pipeline-review-h2-2016>

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Blepharitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Blepharitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Have any query @ <https://www.wiseguyreports.com/enquiry/643474-blepharitis-pipeline-review-h2-2016>

Table of Content

Blepharitis Overview 6

Therapeutics Development 7

Pipeline Products for Blepharitis - Overview 7

Blepharitis - Therapeutics under Development by Companies 8

Blepharitis - Pipeline Products Glance	9
Late Stage Products	9
Clinical Stage Products	10
Early Stage Products	11
Blepharitis - Products under Development by Companies	12
Blepharitis - Companies Involved in Therapeutics Development	13
Allergan Plc	13
InSite Vision Incorporated	14
Kala Pharmaceuticals, Inc.	15
NicOx S.A.	16
Quorum Innovations LLC	17
Senju Pharmaceutical Co., Ltd.	18
Blepharitis - Therapeutics Assessment	19
Assessment by Monotherapy Products	19
Assessment by Target	20
Assessment by Mechanism of Action	22
Assessment by Route of Administration	24
Assessment by Molecule Type	26
Drug Profiles	28
AGN-195263 - Drug Profile	28
Product Description	28
Mechanism Of Action	28
R&D Progress	28
azithromycin - Drug Profile	29
Product Description	29
Mechanism Of Action	29
R&D Progress	29
azithromycin - Drug Profile	30
Product Description	30
Mechanism Of Action	30
R&D Progress	30
dexamethasone acetate - Drug Profile	31
Product Description	31
Mechanism Of Action	31
R&D Progress	31
fluticasone propionate - Drug Profile	33
Product Description	33
Mechanism Of Action	33
R&D Progress	33
ISV-405 - Drug Profile	34
Product Description	34
Mechanism Of Action	34
R&D Progress	34

Ioteprednol etabonate - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Qi-305 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Blepharitis - Dormant Projects 40

Blepharitis - Product Development Milestones 41

Featured News & Press Releases 41

Jul 08, 2014: InSite Vision Plans to Submit New Drug Application to FDA for DexaSite for the Treatment of Blepharitis in Adults 41

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=643474

Continued...

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)□

Norah Trent

[wiseguyreports](https://www.wiseguyreports.com)

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/345413981>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.